Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by equities researchers at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other research firms also recently weighed in on MSTX. Zacks Investment Research downgraded shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Roth Capital reaffirmed a “buy” rating and issued a $2.00 price target on shares of Mast Therapeutics in a research note on Friday, July 15th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $3.00 price target on shares of Mast Therapeutics in a research note on Thursday, July 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $3.33.

Mast Therapeutics (NASDAQ:MSTX) traded down 79.153% on Wednesday, hitting $0.123. The company had a trading volume of 125,838,507 shares. The stock’s market cap is $26.05 million. The firm’s 50 day moving average price is $0.46 and its 200 day moving average price is $0.38. Mast Therapeutics has a 12-month low of $0.10 and a 12-month high of $0.71.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Mast Therapeutics (NASDAQ:MSTX) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. Equities analysts predict that Mast Therapeutics will post ($0.21) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. raised its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned approximately 3.11% of Mast Therapeutics worth $2,818,000 as of its most recent SEC filing.

About Mast Therapeutics

5 Day Chart for NASDAQ:MSTX

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with's FREE daily email newsletter.